Synthesis Of Benzodiazepine Derivatives

Abstract

The invention relates to processes for the synthesis of benzodiazepine derivatives of Formula I: (I)

1 . A process for producing a compound of formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
       
       R 1  is:
   —CH 2 C(O)C(R 2 )(R 3 )-L-R 4  or —CH 2 CHOHC(R 2 )(R 3 )-L-R 4 ,   (i)
 
 
       in which:
 R 2  and R 3  are each, independently, H or C 1-3  aliphatic, halo, or C 1-3  haloaliphatic, or wherein R 2  and R 3  together with the intervening carbon atom to which they are bonded, form a C 3-6  carbocyclic moiety; 
 L is a bond or C 1-3  alkylene; and 
 R 4  is —OR 5  or —SR 5 , wherein R 5  is hydrogen, optionally substituted alkyl, a protecting group or —C(O)R 6 , wherein R 6  is optionally substituted aliphatic, heteroaliphatic, aromatic or heteroaromatic moiety; 
 
       W and X are, independently, hydrogen, halo, C 1-8  alkyl or C 1-8  alkoxy; and 
       rings A and B are each, independently, a monocyclic aryl or heteroaryl, optionally substituted with one or more substituents independently selected from halo, hydroxy, amino, nitro, carboxyl, carboxamido, cyano, —SO 3 H, and optionally substituted C 1-8  alkyl, C 1-8  alkoxy, C 1-8  alkylamino or di(C 1-8  alkyl)amino,
 wherein any one or more substituent on R 1 , ring A or ring B may be unprotected or in a protected form; 
 wherein the process comprises: 
 providing a reaction mixture by adding a compound of formula (I-A), a compound of formula (I-B) and a phosgene synthetic equivalent or phosgene to an aprotic solvent, to form a compound of formula (I) 
 
       
         
           
           
               
               
           
         
         wherein the phosgene synthetic equivalent is carbonyldiimidazole (CDI), diphosgene, triphosgene, a chloroformate or disuccinimidyl carbonate. 
       
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . The process of  claim 1 , wherein the phosgene synthetic equivalent or phosgene is carbonyldiimidazole. 
     
     
         5 . The process of  claim 1 , wherein the process comprises the additional step of deprotection to remove one or more protecting groups, wherein any one or more substituents on R 1 , ring A or ring B is in a protected form. 
     
     
         6 . The process of  claim 1 , wherein the process comprises step (a) of providing a reaction mixture by adding a compound of formula (I-A), a compound of formula (I-B) and a phosgene synthetic equivalent or phosgene to an aprotic solvent, to form a compound of formula (I), wherein the compound of formula (I-A) and the phosgene synthetic equivalent or phosgene are added to the solvent prior to addition of the compound of formula (I-B). 
     
     
         7 . The process of  claim 1 , wherein the aprotic solvent is ethyl acetate, dichloromethane, acetonitrile or toluene. 
     
     
         8 . The process of  claim 1 , wherein R 1  is —CH 2 C(O)C(R 2 )(R 3 )-L-R 4 . 
     
     
         9 . The process of  claim 1 , wherein:
 (a) at least one of ring A and ring B is unsubstituted or substituted phenyl or pyridyl; and/or   (b) W and X are, independently H, halo, C, 1-3  alkyl or C 1-3  alkoxy.   
     
     
         10 . The process of  claim 1 , wherein:
 (a) at least one of ring A and ring B is unsubstituted, monosubstituted or disubstituted phenyl or unsubstituted, monosubstituted or disubstituted 2-, 3- or 4-pyridyl: and/or   (b) W and X are both H.   
     
     
         11 . The process of  claim 1 , wherein ring A is phenyl having a meta substituent chosen from NHMe, NMeEt, NEt 2 , F, Cl, Br, OH, OCH 3 , NH 2 , NMe 2 , NO 2 , Me, (CH 2 ) n —CO 2 H, CN, CH 2 NMe 2 , NHCHO and (CH 2 ) n —SO 3 H where n is 0-2; unsubstituted phenyl or 2-, 3- or 4-pyridyl optionally with a substituent selected from F, Cl, CH 3  and CO 2 H; and Ring B is 2-, 3- or 4-pyridyl or phenyl. 
     
     
         12 . The process of  claim 1 , wherein the compound of formula (I) is a compound of formula (II): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein R 2 , R 3 , L and R 4  are as defined in  claim 1 , the compound of formula (I-A) is a compound of formula (II-A), and the compound of formula (I-B) is a compound of formula (II-B) 
       
       
         
           
           
               
               
           
         
         wherein PG is a protecting group, optionally a Boc protecting group. 
       
     
     
         13 . The process of  claim 1  any preceding claim, wherein R 2  and R 3  together with the intervening carbon atom to which they are bonded, form a C 3 - 4  carbocyclic moiety, or wherein R 2  and R 3  are each, independently, H or C 1-2  alkyl; and L is a bond or C 1-3  alkylene. 
     
     
         14 . The process of  claim 1 , wherein R 2  and R 3  are each, independently, C 1-2  alkyl and L is —CH 2 —. 
     
     
         15 . The process of  claim 1 , wherein R 1  is —CH 2 C(O)C(R 2 )(R 3 )-L-R 4 , R 4  is —OR 5  or —SR 5 , R 5  is hydrogen, methyl or —C(O)R 6 , and R 6  is optionally substituted aliphatic, heteroaliphatic, aromatic or heteroaromatic moiety. 
     
     
         16 . The process of  claim 1 , wherein R 6  is substituted or unsubstituted C 1-6  aliphatic. 
     
     
         17 . The process of  claim 1 , wherein R 6  is methyl. 
     
     
         18 . The process of  claim 1 , wherein R 4  is —OR 5  and R 5  is —C(O)R 6 . 
     
     
         19 . The process of  claim 1 , wherein the compound of formula (I) or (II) is a compound selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         20 . The process of  claim 19 , wherein the compound is selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         21 . The process of  claim 1 , wherein the compound of formula (I) or (II) is a compound of formula (III): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein R 11  is selected from 
       
       
         
           
           
               
               
           
         
       
     
     
         22 . The process of  claim 21 , wherein the compound is a compound of formula (IV): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         23 . The process of  claim 1 , wherein the compound of formula (I) or (II) is a compound (TR) or (TR-A): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         24 . The process of  claim 23 , wherein the compound is a compound (TR2) or (TR2-A): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         25 . (canceled) 
     
     
         26 . A process according to  claim 1  for producing a compound of formula (TR2-A): 
       
         
           
           
               
               
           
         
         wherein the process comprises:
 (a) providing a reaction mixture by adding a compound of formula (II-A), a compound of formula (II-Ba) and a phosgene synthetic equivalent or phosgene to an aprotic solvent, to form a compound of formula (TR2-A-PG) 
 
       
       
         
           
           
               
               
           
         
         wherein PG is a protecting group, optionally a Boc protecting group; and 
         (b) deprotecting the compound of formula (TR2-A-PG) to form a compound of formula (TR2-A). 
       
     
     
         27 - 29 . (canceled)